| __timestamp | Amgen Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 4297000000 | 1513000 |
| Thursday, January 1, 2015 | 4070000000 | 12573000 |
| Friday, January 1, 2016 | 3840000000 | 42238000 |
| Sunday, January 1, 2017 | 3562000000 | 69800000 |
| Monday, January 1, 2018 | 3737000000 | 113773000 |
| Tuesday, January 1, 2019 | 4116000000 | 179362000 |
| Wednesday, January 1, 2020 | 4207000000 | 266946000 |
| Friday, January 1, 2021 | 4819000000 | 438633000 |
| Saturday, January 1, 2022 | 4434000000 | 461645000 |
| Sunday, January 1, 2023 | 4784000000 | 387332000 |
Data in motion
In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Amgen Inc., a stalwart in the industry, has consistently invested heavily in R&D, with expenditures peaking at nearly 4.8 billion in 2023. This represents a steady increase of approximately 34% from 2014. In contrast, CRISPR Therapeutics AG, a pioneer in gene-editing technology, has shown a remarkable growth trajectory in its R&D spending. Starting from a modest base in 2014, CRISPR's R&D expenses surged by over 25,000% by 2022, reflecting its aggressive push into cutting-edge research. This juxtaposition highlights the diverse strategies of established giants and emerging disruptors in the biotech sector. As the industry continues to evolve, these investments will likely shape the future of medical breakthroughs.
R&D Insights: How Amgen Inc. and Pharming Group N.V. Allocate Funds
Research and Development Expenses Breakdown: Amgen Inc. vs Soleno Therapeutics, Inc.
Comparing Innovation Spending: Amgen Inc. and Ligand Pharmaceuticals Incorporated
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: United Therapeutics Corporation vs CRISPR Therapeutics AG
Analyzing R&D Budgets: Insmed Incorporated vs CRISPR Therapeutics AG
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs CRISPR Therapeutics AG
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs Mesoblast Limited
CRISPR Therapeutics AG vs Galapagos NV: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.